David Cooper
CEO Biagon Inc
David Cooper is CEO of Biagon, an AI-driven drug discovery company developing next-generation GPCR therapeutics. He leads Biagon’s strategy and drug discovery programs, integrating computational modeling, molecular dynamics, and experimental pharmacology to identify differentiated, pathway-selective GPCR ligands. Biagon’s pipeline spans metabolic disease and oncology, with a focus on translating advanced computational approaches into novel therapeutic candidates.
Seminars
Tuesday 2nd March 2027
Validating Machine Learning-Designed Biased Agonism to Unlock Precision GPCR Therapeutics
10:00 am
- Demonstrating how Biagon’s machine learning platform integrates structural, experimental and computational data to predict GPCR signaling outcomes and guide the rational design of biased agonists
- Showcasing results in studies from obesity, pain and oncology programs demonstrating successful translation from computational prediction to experimental validation
- Exploring how predictive biased agonism can improve therapeutic selectivity and accelerate the development of next-generation GPCR-targeted medicines
